DCI Announces Latest Release of SureLynx, the Leading Electronic Data Capture Application for Early Stage Clinical Trials
Data Capture International, Inc. (DCI), an emerging Application Service Provider that offers Electronic Data Capture (EDC) software solutions and services to pharmaceutical companies and Contract Research Organizations (CRO's) that perform Phase I (early stage) human clinical trials, announced the release of SureLynx(TM) V2.0.
MARIETTA, Ga., April 26, 2005 /PRNewswire/ -- Data Capture International, Inc. (DCI), an emerging Application Service Provider that offers Electronic Data Capture (EDC) software solutions and services to pharmaceutical companies and Contract Research Organizations (CRO's) that perform Phase I (early stage) human clinical trials, announced the release of SureLynx(TM) V2.0.
SureLynx is DCI's flagship product and consists of a software application for increasing efficiency, improving data quality, and providing standardization for the collection of data in Phase I clinical trials. In addition to the software application, state-of-the-art bar code technology and radio-frequency transmission are combined with approved clinical trial methodologies to yield a product and process that have been proven in the practical setting and provide significant advantages over other systems.
Troy W. McCall, Ph.D., President, said, "The release of SureLynx V2.0 marks an important milestone in our evolution. Our ongoing development efforts ensure that our clients will continue to use state-of-the-art technologies to gain competitive advantages in conducting early stage clinical trials."
"SureLynx is self-directed, self-checking, mobile, user-friendly, and compliant with the strict regulations set forth in 21 CFR Part 11," said Deborah Rucker, Vice President, Business Development. "Our experience, which spans more than 15 years with earlier versions, has been critical in developing the most adaptable system available in the market today."
Dr. McCall continued, "While there are numerous EDC applications available for the collection of clinical data, SureLynx is the only one designed exclusively for early stage trials. This ensures the highest quality data will be efficiently collected in a cost-competitive manner."
Company Background
Data Capture International, Inc. (DCI) was founded to enhance pharmaceutical development by providing value-added software solutions and services for Phase I clinical trials. The company's mission is to be the leading provider of automated identification and data capture technology and systems supporting pharmaceutical product development.
CONTACT: Deborah Rucker, Vice President, Business Development of DataCapture International, Inc., +1-813-654-0132, or drucker@datacaptureintl.com
Web site: www.datacaptureintl.com/
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
